Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Emergency, Tongji Hospital, Tongji Medical College, Science and Technology, Huazhong University, Wuhan, China.
Front Endocrinol (Lausanne). 2022 Apr 7;13:851941. doi: 10.3389/fendo.2022.851941. eCollection 2022.
The cardiovascular complications contribute to a majority of diabetes associated morbidity and mortality, accounting for 44% of death in those patients with type 1 diabetes mellitus (DM) and 52% of deaths in type 2 DM. Diabetes elicits cardiovascular dysfunction through 2 major mechanisms: ischemic and non-ischemic. Non-ischemic injury is usually under-recognized although common in DM patients, and also a pathogenic factor of heart failure in those diabetic individuals complicated with ischemic heart disease. Diabetic cardiomyopathy (DCM) is defined as a heart disease in which the myocardium is structurally and functionally abnormal in the absence of coronary artery disease, hypertensive, valvular, or congenital heart disorders in diabetic patients, theoretically caused by non-ischemic injury solely. Current therapeutic strategies targeting DCM mainly address the increased blood glucose levels, however, the effects on heart function are disappointed. Accumulating data indicate endothelial dysfunction plays a critical role in the initiation and development of DCM. Hyperglycemia, hyperinsulinemia, and insulin resistance cause the damages of endothelial function, including barrier dysfunction, impaired nitric oxide (NO) activity, excessive reactive oxygen species (ROS) production, oxidative stress, and inflammatory dysregulation. In turn, endothelial dysfunction promotes impaired myocardial metabolism, intracellular Ca mishandling, endoplasmic reticulum (ER) stress, mitochondrial defect, accumulation of advanced glycation end products, and extracellular matrix (ECM) deposit, leads to cardiac stiffness, fibrosis, and remodeling, eventually results in cardiac diastolic dysfunction, systolic dysfunction, and heart failure. While endothelial dysfunction is closely related to cardiac dysfunction and heart failure seen in DCM, clinical strategies for restoring endothelial function are still missing. This review summarizes the timely findings related to the effects of endothelial dysfunction on the disorder of myocardium as well as cardiac function, provides mechanical insights in pathogenesis and pathophysiology of DCM developing, and highlights potential therapeutic targets.
心血管并发症是导致糖尿病相关发病率和死亡率的主要原因,占 1 型糖尿病 (DM) 患者死亡的 44%,2 型 DM 患者死亡的 52%。糖尿病通过两种主要机制引起心血管功能障碍:缺血性和非缺血性。非缺血性损伤在糖尿病患者中很常见,但通常未被认识到,也是合并缺血性心脏病的糖尿病个体心力衰竭的致病因素。糖尿病心肌病 (DCM) 是指在没有冠状动脉疾病、高血压、瓣膜或先天性心脏病的糖尿病患者中,心肌结构和功能异常的心脏病,理论上仅由非缺血性损伤引起。目前针对 DCM 的治疗策略主要针对血糖升高,但对心脏功能的影响令人失望。越来越多的证据表明内皮功能障碍在 DCM 的发生和发展中起关键作用。高血糖、高胰岛素血症和胰岛素抵抗导致内皮功能受损,包括屏障功能障碍、一氧化氮 (NO) 活性受损、活性氧 (ROS) 产生过多、氧化应激和炎症失调。反过来,内皮功能障碍会促进心肌代谢受损、细胞内 Ca 处理异常、内质网 (ER) 应激、线粒体缺陷、晚期糖基化终产物的积累和细胞外基质 (ECM) 沉积,导致心脏僵硬度增加、纤维化和重塑,最终导致心脏舒张功能障碍、收缩功能障碍和心力衰竭。虽然内皮功能障碍与 DCM 中观察到的心脏功能障碍和心力衰竭密切相关,但恢复内皮功能的临床策略仍存在缺失。本综述总结了与内皮功能障碍对心肌紊乱及心脏功能的影响相关的最新发现,为 DCM 发病机制和病理生理学提供了力学见解,并强调了潜在的治疗靶点。
Front Endocrinol (Lausanne). 2022
Int J Mol Sci. 2019-7-2
Endocr Metab Immune Disord Drug Targets. 2021
Acta Pharmacol Sin. 2018-6-4
Front Endocrinol (Lausanne). 2025-8-8
Front Endocrinol (Lausanne). 2025-7-23
Front Endocrinol (Lausanne). 2025-7-17
Front Endocrinol (Lausanne). 2025-6-5
Diabetol Metab Syndr. 2025-6-10
Int J Mol Sci. 2025-5-9
Front Cell Dev Biol. 2021-5-19
Antioxidants (Basel). 2021-5-3
Cardiovasc Res. 2022-1-7
J Am Coll Cardiol. 2020-12-15
Nat Commun. 2020-10-15
Nature. 2020-12
Basic Res Cardiol. 2020-5-25